{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:09:21Z","timestamp":1761844161326},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,2,3]],"date-time":"2012-02-03T00:00:00Z","timestamp":1328227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00280-012-1835-9","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T13:37:16Z","timestamp":1328621836000},"page":"1307-1314","source":"Crossref","is-referenced-by-count":10,"title":["Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index"],"prefix":"10.1007","volume":"69","author":[{"given":"Thea Eline","family":"Hetland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janne","family":"K\u00e6rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Skrede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berit","family":"Sandstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claes","family":"Trop\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivi Ann","family":"Fl\u00f8renes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,3]]},"reference":[{"issue":"Suppl 1","key":"1835_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0020-7292(03)90118-4","volume":"83","author":"AP Heintz","year":"2003","unstructured":"Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Pecorelli S (2003) Carcinoma of the ovary. Int J Gynaecol Obstet 83(Suppl 1):135\u2013166","journal-title":"Int J Gynaecol Obstet."},{"key":"1835_CR2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","volume":"351","author":"SA Cannistra","year":"2004","unstructured":"Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519\u20132529","journal-title":"N Engl J Med"},{"key":"1835_CR3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analyses. J Clin Oncol 20:1248\u20131259","journal-title":"J Clin Oncol"},{"key":"1835_CR4","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trope CG, Amant F et al (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363:943\u2013953","journal-title":"N Engl J Med"},{"key":"1835_CR5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00001622-200209000-00008","volume":"14","author":"E Salom","year":"2002","unstructured":"Salom E, Almeida Z, Mirhashemi R (2002) Management of recurrent ovarian cancer: evidence-based decisions. Curr Opin Oncol 14:519\u2013527","journal-title":"Curr Opin Oncol"},{"key":"1835_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1634\/theoncologist.5-1-26","volume":"5","author":"M Markman","year":"2000","unstructured":"Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5:26\u201335","journal-title":"Oncologist"},{"key":"1835_CR7","doi-asserted-by":"crossref","unstructured":"Pujade-Lauraine E, Mahner S, Kaern J et al (2009) A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the gynecologic cancer intergroup (GCIG). J Clin Oncol 27:No 18s","DOI":"10.1200\/jco.2009.27.18s.lba5509"},{"key":"1835_CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1586\/era.09.165","volume":"10","author":"P Harter","year":"2010","unstructured":"Harter P, Hilpert F, Mahner S, Heitz F, Pfisterer J, du Bois A (2010) Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs. Expert Rev Anticancer Ther 10:81\u201388","journal-title":"Expert Rev Anticancer Ther"},{"key":"1835_CR9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/GCO.0b013e32832210ff","volume":"21","author":"IA Cree","year":"2009","unstructured":"Cree IA (2009) Chemosensitivity and chemoresistance testing in ovarian cancer. Curr Opin Obstet Gynecol 21:39\u201343","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1835_CR10","first-page":"5276","volume":"55","author":"PE Andreotti","year":"1995","unstructured":"Andreotti PE, Cree IA, Kurbacher CM et al (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276\u20135282","journal-title":"Cancer Res"},{"key":"1835_CR11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/CAD.0b013e3281de727e","volume":"18","author":"IA Cree","year":"2007","unstructured":"Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S, Ovarian Cancer Trial Group TCA (2007) A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician\u2019s choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18:1093\u20131101","journal-title":"Anticancer Drugs"},{"key":"1835_CR12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1007\/s00432-009-0598-0","volume":"135","author":"HS Kim","year":"2009","unstructured":"Kim HS, Kim TJ, Chung HH, Kim JW, Kim BG, Park NH, Song YS, Bae DS, Kang SB (2009) In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. J Cancer Res Clin Oncol 135:1513\u20131520","journal-title":"J Cancer Res Clin Oncol"},{"key":"1835_CR13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1006\/gyno.2000.5728","volume":"77","author":"G Konecny","year":"2000","unstructured":"Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M (2000) Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77:258\u2013263","journal-title":"Gynecol Oncol"},{"key":"1835_CR14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1067\/S0002-9378(03)00629-X","volume":"189","author":"V Loizzi","year":"2003","unstructured":"Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189:1301\u20131307","journal-title":"Am J Obstet Gynecol"},{"key":"1835_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2407-3-19","volume":"3","author":"S Sharma","year":"2003","unstructured":"Sharma S, Neale MH, Di Nicolantonio F et al (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer 3:19","journal-title":"BMC Cancer"},{"key":"1835_CR16","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1994.12.9.1748","volume":"12","author":"JT Thigpen","year":"1994","unstructured":"Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12:1748\u20131753","journal-title":"J Clin Oncol"},{"key":"1835_CR17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"1835_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1006\/gyno.2002.6797","volume":"87","author":"RW Holloway","year":"2002","unstructured":"Holloway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ, Fruehauf JP (2002) Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87:8\u201316","journal-title":"Gynecol Oncol"},{"key":"1835_CR19","first-page":"949","volume":"28","author":"H Neubauer","year":"2008","unstructured":"Neubauer H, Stefanova M, Solomayer E, Meisner C, Zwirner M, Wallwiener D, Fehm T (2008) Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer. Anticancer Res 28:949\u2013955","journal-title":"Anticancer Res"},{"key":"1835_CR20","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/1097-0142(19940401)73:7<1870::AID-CNCR2820730716>3.0.CO;2-3","volume":"73","author":"J Kaern","year":"1994","unstructured":"Kaern J, Trope CG, Kristensen GB, Pettersen EO (1994) Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma. Cancer 73:1870\u20131877","journal-title":"Cancer"},{"key":"1835_CR21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/archsurg.1983.01390120036010","volume":"118","author":"CA Bertelsen","year":"1983","unstructured":"Bertelsen CA, Korn EI, Morton DL, Kern DH (1983) Heterogeneity of human metastatic clones by in vitro chemosensitivity testing. Implications for the clinical application of the clonogenic assay. Arch Surg 118:1406\u20131409","journal-title":"Arch Surg"},{"key":"1835_CR22","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2008.05.019","volume":"110","author":"JN McAlpine","year":"2008","unstructured":"McAlpine JN, Eisenkop SM, Spirtos NM (2008) Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays. Gynecol Oncol 110:360\u2013364","journal-title":"Gynecol Oncol"},{"key":"1835_CR23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ygyno.2005.04.036","volume":"98","author":"KS Tewari","year":"2005","unstructured":"Tewari KS, Mehta RS, Burger RA et al (2005) Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol 98:360\u2013368","journal-title":"Gynecol Oncol"},{"key":"1835_CR24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00404-009-1121-1","volume":"281","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Eno ML, Im DD, Rosenshein NB (2010) Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Arch Gynecol Obstet 281:325\u2013328","journal-title":"Arch Gynecol Obstet"},{"key":"1835_CR25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000279386","volume":"77","author":"AD Tiersten","year":"2009","unstructured":"Tiersten AD, Moon J, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS (2009) Chemotherapy resistance as a predictor of progression-free survival in ovarian cancer patients treated with neoadjuvant chemotherapy and surgical cytoreduction followed by intraperitoneal chemotherapy: a Southwest Oncology Group Study. Oncology 77:395\u2013399","journal-title":"Oncology"},{"key":"1835_CR26","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","volume":"12","author":"SL Cooke","year":"2011","unstructured":"Cooke SL, Brenton JD (2011) Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol 12:1169\u20131174","journal-title":"Lancet Oncol"},{"key":"1835_CR27","unstructured":"du Bois A, Harter P (2010) Understanding and optimizing the potential role of surgical debulking in advanced epithelial ovarian cancer. ASGO 2010 Educational Book\u2014Category. Gynecologic cancer: e13\u2013e17"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1835-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-012-1835-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-012-1835-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T05:15:01Z","timestamp":1561266901000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-012-1835-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,3]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["1835"],"URL":"https:\/\/doi.org\/10.1007\/s00280-012-1835-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,3]]}}}